Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn
NCT ID: NCT00701259
Last Updated: 2010-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
852 participants
INTERVENTIONAL
2007-01-31
2007-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
NCT00389948
Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn
NCT00390390
Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of Heartburn
NCT01037452
Safety and Efficacy of Lansoprazole in Patients With Reflux Disease
NCT01135368
Safety and Efficacy of Lansoprazole 30mg Twice Daily in Treatment of Laryngitis Associated With Gastroesophageal Reflux
NCT00369265
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
15 mg lansoprazole
Lansoprazole
Lansoprazole 15 mg once per day for 14 days
2
30 mg lansoprazole
Lansoprazole
Lansoprazole 30 mg once per day for 14 days
3
placebo
placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lansoprazole
Lansoprazole 15 mg once per day for 14 days
Lansoprazole
Lansoprazole 30 mg once per day for 14 days
placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Having heartburn that responds to heartburn medication.
* Be willing to discontinue the use of heartburn treatment for 7 days prior to inclusion in the study.
Exclusion Criteria
* Be unwilling to take only the study medication, and antacid provided as a rescue medication for relief of acute heartburn during the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Novartis
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Not applicable - enrollment complete
Parsippany, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRSW-GN-305
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.